Antibody Directs Properdin-Dependent Activation of the Complement Alternative Pathway in a Mouse Model of Abdominal Aortic Aneurysm

Total Page:16

File Type:pdf, Size:1020Kb

Antibody Directs Properdin-Dependent Activation of the Complement Alternative Pathway in a Mouse Model of Abdominal Aortic Aneurysm Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm Hui-fang Zhoua, Huimin Yana, Cordula M. Stoverb, Tamara Montes Fernandezc, Santiago Rodriguez de Cordobac, Wen-Chao Songd, Xiaobo Wua,RobertW.Thompsone, Wilhelm J. Schwaebleb, John P. Atkinsona, Dennis E. Hourcadea,1,andChristineT.N.Phama,1 aDivision of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110; bDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester LE1 9HN, United Kingdom; cDepartment of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CSIC) and Ciber de Enfermedades Raras (CIBERER), 28040 Madrid, Spain; dInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; and eSection of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110 AUTHOR SUMMARY Abdominal aortic aneurysm response, in general, and pro- (AAA) is a complex, inflam- perdin, in particular, merit matory vascular disease, and it is additional exploration. among the top 20 leading causes Properdin is found systemi- of death in the United States. cally in the circulation but is also Surgical repair is currently the stored and rapidly released from only option for management. the granule components of However, mortality and morbid- a type of immune cells called ity are significant even after neutrophils during cell stimula- elective surgery, especially in the tion. We showed that, although older patients who are commonly addition of an outside source of affected. A better understanding neutrophils to properdin-de- Fig. P1. Proposed mechanism of AP complement activation and fi of the underlying immune-medi- order of events in elastase-induced AAA disease. (1) Elastase cient mice could deliver the ated inflammatory pathways in- perfusion unmasks hidden neoepitopes (newly exposed self-antigens) properdin needed to cause AAA volved in AAA may lead to that are recognized by IgG antibody, providing a platform for to some extent, adding pro- treatments that could halt dis- properdin-stabilized AP C3 convertase (C3bBbP) assembly. (2) perdin in the form of mouse se- ease progression. Here, we found Complement activation leads to the release of anaphylatoxins (C3a rum is fully sufficient to promote roles for a particular protein, and C5a. (3) These molecules attract immune cells called neutrophils. aneurysm formation in our fi (4) Activated neutrophils release chemicals that attract other mouse model. To determine properdin, and speci c natural inflammatory immune cells, including monocytes and macrophages. antibodies in the genesis (5) Macrophages release proteases and other inflammatory mediators whether properdin initiates the of AAA. that cause structural damage (weakening of the aortic wall) and AP, we induced a substitution The complement system is eventual aneurysmal changes characteristic of AAA. mutation, D279A, of human a part of the immune system that factor B (fB), an essential com- can rapidly respond to foreign ponent of the AP that is a pro- intruders without prior exposure, causing inflammation and activator of C3. This substitution, which has been described in other biological responses. Complement is activated through previous studies (4), produces a stable C3 convertase in the three pathways, including the alternative pathway (AP), which absence of properdin. We reasoned that, if the essential role of operates continuously because of hydrolysis of the protein C3. properdin in AAA development is to stabilize the AP convertase, We previously established that the AP plays a major role in AAA then the introduction of such a stabilizing fB mutant protein development (1); however, the molecular mechanisms behind into properdin-deficient animals would compensate for the this role remained undefined. properdin deficiency, restoring AAA pathology. For these Properdin is a component of the AP C3 convertase, a critical experiments, a D279G-equivalent mouse fB mutant protein, enzyme in the AP activation pathway. Properdin has long been D276G, was generated. Introduction of D276G protein into known to stabilize this otherwise short-lived molecular complex properdin-deficient mice restored susceptibility to aneurysm (2). Recently, evidence has accumulated that properdin can development, suggesting that the critical function of properdin in also bind certain cellular and microbial surfaces and provide this case is stabilization of the AP convertase and not initiation. a platform for AP C3 convertase assembly and function (3). We previously found compelling evidence for an association of properdin with human AAA (1). In the present study, we sought Author contributions: H.-f.Z., H.Y., D.E.H., and C.T.N.P. designed research; H.-f.Z., H.Y., to test the hypothesis that properdin plays a central role in T.M.F., and C.T.N.P. performed research; C.M.S., T.M.F., S.R.d.C., W.-C.S., X.W., and W.J.S. AAA development with a model of AAA induced by transient contributed new reagents/analytic tools; H.-f.Z., H.Y., T.M.F., D.E.H., and C.T.N.P. analyzed perfusion of elastase (an enzyme that breaks down proteins). data; and C.M.S., S.R.d.C., R.W.T., W.J.S., J.P.A., D.E.H., and C.T.N.P. wrote the paper. Using properdin-deficient mice, we first confirmed that pro- The authors declare no conflict of interest. perdin is required for AP complement-mediated acute in- This article is a PNAS Direct Submission. flammatory response in elastase-induced AAA. Mice deficient 1To whom correspondence may be addressed. E-mail: [email protected] or in properdin were protected against aneurysm formation. [email protected]. Blockade of properdin activity also protected against AAA de- See full research article on page E415 of www.pnas.org. velopment, suggesting that strategies that target the complement Cite this Author Summary as: PNAS 10.1073/pnas.1119000109. 2202–2203 | PNAS | February 14, 2012 | vol. 109 | no. 7 www.pnas.org/cgi/doi/10.1073/pnas.1119000109 Downloaded by guest on October 2, 2021 Several studies have previously described the presence of a molecule recognized by an antibody) that bind natural IgG PNAS PLUS antibodies or Igs in human AAA tissues, but it has proven dif- antibodies, and the resulting surface-bound Igs provide pro- ficult to establish a causative role for these antibodies in AAA. tected sites that promote the assembly and activation of pro- In general, antibodies are immune system molecules that rec- perdin-stabilized AP C3 convertase. The ensuing generation of ognize and bind foreign invaders. IgM antibodies are usually anaphylatoxins (C3a and C5a) by the convertases results in produced immediately after exposure to foreign invaders, activation and recruitment of immune cells to the site of injury, whereas IgG antibodies evolve later in the immune response. where they initiate inflammation that causes the formation of Natural antibodies (IgM and IgG), however, are Igs present in an AAA (Fig. P1). individual before foreign invader exposure. Natural antibodies Collectively, our results suggest that properdin plays a critical can bind to self-antigens (i.e., act as autoantibodies in recog- role in AAA development. It, therefore, represents a potentially nizing constituents of the body’s own tissues). Because properdin attractive therapeutic target given that it is unique to the AP did not seem to initiate complement activation, we next in- and present at relatively low concentrations. Moreover, we re- vestigated whether the AP might be activated through an anti- veal an unexpected role for autoantibodies in the pathogenesis of body-dependent mechanism (5). First, we examined aortas AAA. These findings support additional efforts aimed at eluci- obtained from mice perfused with elastase. We found abundant dating the identity of the self-antigens recognized by these IgG, but not IgM, deposition in the aortic wall. autoantibodies, because this identification may yield additional Next, we induced disease in a cohort of μMT mice that are therapeutic targets for this common disorder. deficient in B cells (immune system cells that produce Igs) and hence, deficient in all Igs. The absence of Igs abrogated C3 de- 1. Pagano MB, et al. (2009) Complement-dependent neutrophil recruitment is critical for position in elastase-perfused aortic wall and protected μMT the development of elastase-induced abdominal aortic aneurysm. Circulation 119: mice from AAA development. Moreover, reconstitution with 1805–1813. fi 2. Fearon DT, Austen KF (1975) Properdin: Binding to C3b and stabilization of the C3b- natural mouse IgG antibodies puri ed from normal, unmutated dependent C3 convertase. J Exp Med 142:856–863. mice restored susceptibility to AAA in μMT mice. These results 3. Kemper C, Hourcade DE (2008) Properdin: New roles in pattern recognition and target suggest that natural IgG antibodies recognize an exposed clearance. Mol Immunol 45:4048–4056. self-antigen in the elastase-perfused aortic wall, and their pres- 4. Hourcade DE, Mitchell LM, Oglesby TJ (1999) Mutations of the type A domain of fi ence supports AP activation and aneurysm formation. complement factor B that promote high-af nity C3b-binding. J Immunol 162: 2906–2911. In summary, we propose that, in the AAA mouse model, 5. Ratnoff WD, Fearon DT, Austen KF (1983) The role of antibody in the activation of the elastase treatment unmasks hidden epitopes (i.e., the parts of alternative complement pathway. Springer Semin Immunopathol 6:361–371. IMMUNOLOGY Zhou et al. PNAS | February 14, 2012 | vol. 109 | no. 7 | 2203 Downloaded by guest on October 2, 2021.
Recommended publications
  • C3b Catalog Number: A114 Sizes Available
    Name: C3b Catalog Number: A114 Sizes Available: 250 µg/vial Concentration: 1.0 mg/mL (see Certificate of Analysis for actual concentration) Form: Liquid Purity: >90% by SDS-PAGE Buffer: 10 mM sodium phosphate, 145 mM NaCl, pH 7.3 Extinction Coeff. A280 nm = 1.03 at 1.0 mg/mL Molecular Weight: 176,000 Da (2 chains) Preservative: None, 0.22 µm filtered Storage: -70oC or below. Avoid freeze/thaw. Source: Normal human serum (shown by certified tests to be negative for HBsAg and for antibodies to HCV, HIV-1 and HIV-II). Precautions: Use normal precautions for handling human blood products. Origin: Manufactured in the USA. General Description C3b is derived from native C3 upon cleavage and release of C3a. It is prepared by cleavage with the alternative pathway C3 convertase. This is important because only a single bond in C3 is cleaved by the native convertase, while cleavage by other proteases, such as trypsin, results in multiple cleavages at many other sites in the protein. Native human C3b is a glycosylated (~2.8%) polypeptide containing two disulfide-linked chains. C3b is central to the function of all three pathways of complement (Law, S.K.A. and Reid, K.B.M. (1995)). Initiation of each pathway generates proteolytic enzyme complexes (C3 convertases) which are bound to the target surface. These enzymes cleave a peptide bond in C3 releasing the anaphylatoxin C3a and activating C3b. For a brief time (~60 µs) this nascent C3b is capable of reacting with and covalently coupling to hydroxyl groups on the target surface.
    [Show full text]
  • Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia
    BASIC RESEARCH www.jasn.org Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia Yoshiyasu Ueda,1 Takashi Miwa,1 Damodar Gullipalli,1 Sayaka Sato,1 Daisuke Ito,1 Hangsoo Kim,1 Matthew Palmer,2 and Wen-Chao Song1 Departments of 1Systems Pharmacology and Translational Therapeutics and 2Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania ABSTRACT Background Properdin (P) is a positive regulator of the alternative pathway of complement activation. Although P inhibition is expected and has been shown to ameliorate the alternative pathway of comple- ment-mediated tissue injury in several disease models, it unexpectedly exacerbated renal injury in a murine model of C3 glomerulopathy. The role of P in atypical hemolytic uremic syndrome (aHUS) is uncertain. Methods We blocked P function by genetic deletion or mAb-mediated inhibition in mice carrying a factor H (FH) point mutation, W1206R (FHR/R), that causes aHUS and systemic thrombophilia with high mortality. Results Pdeficiency completely rescued FHR/R mice from premature death and prevented thrombocyto- penia, hemolytic anemia, and renal disease. It also eliminated macrovessel thrombi that were prevalent in FHR/R mice. All mice that received a function-blocking anti-P mAb for 8 weeks survived the experimental period and appeared grossly healthy. Platelet counts and hemoglobin levels were significantly improved in FHR/R mice after 4 weeks of anti-P mAb treatment. One half of the FHR/R mice treated with an isotype control mAb but none of the anti-P mAb-treated mice developed stroke-related neurologic disease. Anti-P mAb-treated FHR/R mice showed largely normal renal histology, and residual liver thrombi were detected in only three of 15 treated mice.
    [Show full text]
  • The 'C3ar Antagonist' SB290157 Is a Partial C5ar2 Agonist
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.01.232090; this version posted August 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The ‘C3aR antagonist’ SB290157 is a partial C5aR2 agonist Xaria X. Li1, Vinod Kumar1, John D. Lee1, Trent M. Woodruff1* 1School of Biomedical Sciences, The University of Queensland, St Lucia, 4072 Australia. * Correspondence: Prof. Trent M. Woodruff School of Biomedical Sciences, The University of Queensland, St Lucia, 4072 Australia. Ph: +61 7 3365 2924; Fax: +61 7 3365 1766; E-mail: [email protected] Keywords: Complement C3a, C3aR, SB290157, C5aR1, C5aR2 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.01.232090; this version posted August 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abbreviations used in this article: BRET, bioluminescence resonance energy transfer; BSA, bovine serum albumin; C3aR, C3a receptor C5aR1, C5a receptor 1; CHO-C3aR, Chinese hamster ovary cells stably expressing C3aR; CHO-C5aR1, Chinese hamster ovary cells stably expressing C5aR1; DMEM, Dulbecco's Modified Eagle's Medium; ERK1/2, extracellular signal-regulated kinase 1/2; FBS, foetal bovine serum; HEK293, human embryonic kidney 293 cells; HMDM, human monocyte-derived macrophage; i.p., intraperitoneal; i.v., intravenous; rhC5a, recombinant human C5a; RT, room temperature; S.E.M.
    [Show full text]
  • Properdin Contributes to Allergic Airway Inflammation Through Local C3a Generation Yuan Wang, Takashi Miwa, Blerina Ducka-Kokalari, Imre G
    Properdin Contributes to Allergic Airway Inflammation through Local C3a Generation Yuan Wang, Takashi Miwa, Blerina Ducka-Kokalari, Imre G. Redai, Sayaka Sato, Damodar Gullipalli, James G. This information is current as Zangrilli, Angela Haczku and Wen-Chao Song of September 26, 2021. J Immunol 2015; 195:1171-1181; Prepublished online 26 June 2015; doi: 10.4049/jimmunol.1401819 http://www.jimmunol.org/content/195/3/1171 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2015/06/26/jimmunol.140181 Material 9.DCSupplemental http://www.jimmunol.org/ References This article cites 66 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/195/3/1171.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 26, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Properdin Contributes to Allergic Airway Inflammation through Local C3a Generation Yuan Wang,* Takashi Miwa,* Blerina Ducka-Kokalari,† Imre G.
    [Show full text]
  • The Regulation of Liver Cell Survival by Complement Maciej M
    The Regulation of Liver Cell Survival by Complement Maciej M. Markiewski, Robert A. DeAngelis, Christoph W. Strey, Periklis G. Foukas, Craig Gerard, Norma Gerard, Rick This information is current as A. Wetsel and John D. Lambris of September 27, 2021. J Immunol 2009; 182:5412-5418; ; doi: 10.4049/jimmunol.0804179 http://www.jimmunol.org/content/182/9/5412 Downloaded from References This article cites 33 articles, 5 of which you can access for free at: http://www.jimmunol.org/content/182/9/5412.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The Regulation of Liver Cell Survival by Complement1 Maciej M. Markiewski,2* Robert A. DeAngelis,2* Christoph W. Strey,3* Periklis G. Foukas,* Craig Gerard,† Norma Gerard,† Rick A. Wetsel,‡ and John D.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Complement Receptor CD46 Co-Stimulates Optimal Human CD8 T
    ARTICLE DOI: 10.1038/s41467-018-06706-z OPEN Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism Giuseppina Arbore1,2, Erin E. West3, Jubayer Rahman3, Gaelle Le Friec2, Nathalie Niyonzima3,4, Mehdi Pirooznia 3, Ilker Tunc3, Polychronis Pavlidis2, Nicholas Powell2, Yuesheng Li3, Poching Liu3, Aude Servais5, Lionel Couzi6, Veronique Fremeaux-Bacchi7, Leo Placais3, Alastair Ferraro8, Patrick R. Walsh9, David Kavanagh9, Behdad Afzali 3,10, Paul Lavender2, Helen J. Lachmann11 & Claudia Kemper2,3,12 1234567890():,; The induction of human CD4+ Th1 cells requires autocrine stimulation of the complement receptor CD46 in direct crosstalk with a CD4+ T cell-intrinsic NLRP3 inflammasome. However, it is unclear whether human cytotoxic CD8+ T cell (CTL) responses also rely on an intrinsic complement-inflammasome axis. Here we show, using CTLs from patients with CD46 deficiency or with constitutively-active NLRP3, that CD46 delivers co-stimulatory signals for optimal CTL activity by augmenting nutrient-influx and fatty acid synthesis. Sur- prisingly, although CTLs express NLRP3, a canonical NLRP3 inflammasome is not required for normal human CTL activity, as CTLs from patients with hyperactive NLRP3 activity function normally. These findings establish autocrine complement and CD46 activity as integral components of normal human CTL biology, and, since CD46 is only present in humans, emphasize the divergent roles of innate immune sensors between mice and men. 1 Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy. 2 School of Immunology and Microbial Sciences, King’s College London, London, UK. 3 Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
    [Show full text]
  • Activation of the Complement System on Human Endothelial Cells by Urban Particulate Matter Triggers Inflammation-Related Protein Production
    International Journal of Molecular Sciences Article Activation of the Complement System on Human Endothelial Cells by Urban Particulate Matter Triggers Inflammation-Related Protein Production Myoung Su Choi 1,† , Hyungtaek Jeon 2,†, Seung-Min Yoo 2 and Myung-Shin Lee 2,* 1 Department of Otorhinolaryngology, Eulji University Medical Center, Eulji University School of Medicine, Daejeon 35233, Korea; [email protected] 2 Department of Microbiology and Immunology, Eulji University School of Medicine, Daejeon 34824, Korea; [email protected] (H.J.); [email protected] (S.-M.Y.) * Correspondence: [email protected]; Tel.: +82-42-259-1662 † These authors have contributed equally to this work. Abstract: Exposure to particulate matter (PM) is becoming a major global health issue. The amount and time of exposure to PM are known to be closely associated with cardiovascular diseases. However, the mechanism through which PM affects the vascular system is still not clear. Endothelial cells line the interior surface of blood vessels and actively interact with plasma proteins, including the complement system. Unregulated complement activation caused by invaders, such as pollutants, may promote endothelial inflammation. In the present study, we sought to investigate whether urban PM (UPM) acts on the endothelial environment via the complement system. UPM-treated human endothelial cells with normal human serum showed the deposition of membrane attack complexes Citation: Choi, M.S.; Jeon, H.; Yoo, (MACs) on the cell surface via the alternative pathway of the complement system. Despite the forma- S.-M.; Lee, M.-S. Activation of the tion of MACs, cell death was not observed, and cell proliferation was increased in UPM-mediated Complement System on Human complement activation.
    [Show full text]
  • Innate Immunity: the Inside Story on Complement Activation
    RESEARCH HIGHLIGHTS Nature Reviews Immunology | AOP, published online 31 December 2013; doi:10.1038/nri3603 INNATE IMMUNITY The inside story on complement activation The evolutionarily ancient comple- inconsistent with de novo protein — the production of interferon-γ ment system might have started life production, so the authors looked (IFNγ) and interleukin-17 was sig- as an intracellular activation pathway for a potential role of endogenous nificantly decreased but could be par- rather than as a liver-derived serum proteases. They showed that rest- tially rescued by the addition of C3a. effector cascade. Other recent studies ing human T cells express mRNA Cytokine production was not affected have suggested the importance of encoding cathepsin L (CTSL), and in serum-free medium or in the T cell-derived local complement acti- that CTSL cleaves C3 into biologi- presence of a C3 convertase inhibitor, vation in the autocrine stimulation of cally active C3a and C3b fragments which shows that the CTSL-mediated T helper 1 (T 1) cell responses, but in vitro. C3 and CTSL were found to C3 activation pathway is sufficient H intracellular Claudia Kemper, John Atkinson and be colocalized in resting T cells in for autocrine C3aR-induced T cell colleagues are the first to show that C3a the endoplasmic reticulum (ER) and effector function in humans. the C3 activation products C3a and generation ER-derived secretory vesicles. The in vivo relevance of this C3b can be generated intracellularly … is both Intracellular C3a was detected in pathway was shown in synovial fluid in human CD4+ T cells. resting T cells, and the increase in CD4+ T cells from patients with juve- Activation of mouse T cells is upregulated intracellular C3a levels observed after nile idiopathic arthritis.
    [Show full text]
  • Targeting of Mannan-Binding Lectin-Associated Serine Protease-2 Confers Protection from Myocardial and Gastrointestinal Ischemia/Reperfusion Injury
    Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury Wilhelm J. Schwaeblea,1, Nicholas J. Lyncha, James E. Clarkb, Michael Marberb, Nilesh J. Samanic, Youssif Mohammed Alia,d, Thomas Dudlere, Brian Parente, Karl Lhottaf, Russell Wallisa, Conrad A. Farrarg, Steven Sacksg, Haekyung Leeh, Ming Zhangh, Daisuke Iwakii, Minoru Takahashii, Teizo Fujitai, Clark E. Tedforde, and Cordula M. Stovera Departments of aInfection, Immunity, and Inflammation and cCardiovascular Sciences, University of Leicester, Leicester LE1 9HN, United Kingdom; bBritish Heart Foundation Centre and gMedical Research Council Centre for Transplantation and National Institute for Health Research Biomedical Research Centre at Guy’s and St. Thomas’ National Health Service Foundation Trust, King’s College London, London SE1 9RT, United Kingdom; dFaculty of Pharmacy, Department of Microbiology, University of Mansoura, Mansoura 35516, Egypt; eOmeros Corporation, Seattle, WA 98101; fLandeskrankenhaus Feldkirch, 6807 Feldkirch, Austria; hDepartment of Anesthesiology, State University of New York-Downstate Medical Center, New York, NY 11203; and iDepartment of Immunology, Fukushima Medical University, Fukushima 960-1295, Japan Edited* by Douglas T. Fearon, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, and approved March 16, 2011 (received for review February 1, 2011) Complement research experienced a renaissance with the discovery aberrant glycosylation
    [Show full text]
  • C3a Anaphylatoxin
    Name: C3a Anaphylatoxin (Not Recombinant) Catalog Number: A118 Sizes Available: 50 µg Concentration: 0.5 mg/mL (see Certificate of Analysis for the actual concentration) Extinction Coeff. A276 nm = 0.41 at 1.0 mg/mL Molecular weight: 9089 Da (single chain) Form: Frozen liquid Purity: >97% by SDS-PAGE Buffer: Phosphate buffered saline, pH 7.3 (No carrier proteins added) Preservative None Presence of desArg: < 3 % Storage: -70oC or below. Avoid freeze/thaw. Source: Normal human serum (shown by certified tests to be negative for HBsAg, HTLV-I/II, STS and for antibodies to HCV, HIV-1 and HIV-II). Precautions: Use normal precautions for handling human blood products. Origin: Manufactured in the USA. General Description Natural human C3a is prepared by cleavage of human C3 protein by a human C3 convertase. C3a is a member of the anaphylatoxin family of three proteins (C3a, C4a and C5a) produced by the activation of complement. It is an unglycosylated polypeptide containing 77 amino acids with a molecular mass of 9,089 daltons. Many of the biological functions of C3a are similar to those of C5a, but C3a is approximately 10- to 20-fold less active per microgram than C5a. C3a mediates many inflammatory responses including smooth muscle contraction, vasodilation, increased vascular permeability, and release of histamine from mast cells and basophils (Law, S.K.A. and Reid, K.B.M. (1995)). In contrast to C5a, C3a does not exhibit significant neutrophil stimulating activities and does not induce chemotaxis, granule release or superoxide production. C3a acts through the C3a Receptor (C3aR) which is a G-protein coupled receptor found widely distributed on peripheral tissues, lymphoid cells (neutrohphils, monocyes, and eosinophils) and in the central nervous system (astrocytes, neurons and glial cells) (Law, S.K.A.
    [Show full text]
  • I M M U N O L O G Y Core Notes
    II MM MM UU NN OO LL OO GG YY CCOORREE NNOOTTEESS MEDICAL IMMUNOLOGY 544 FALL 2011 Dr. George A. Gutman SCHOOL OF MEDICINE UNIVERSITY OF CALIFORNIA, IRVINE (Copyright) 2011 Regents of the University of California TABLE OF CONTENTS CHAPTER 1 INTRODUCTION...................................................................................... 3 CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS ..............................................9 CHAPTER 3 ANTIBODY STRUCTURE I..................................................................17 CHAPTER 4 ANTIBODY STRUCTURE II.................................................................23 CHAPTER 5 COMPLEMENT...................................................................................... 33 CHAPTER 6 ANTIBODY GENETICS, ISOTYPES, ALLOTYPES, IDIOTYPES.....45 CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION..................................................................53 CHAPTER 8 GENETIC BASIS OF ANTIBODY DIVERSITY...................................61 CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS ...............................................69 CHAPTER 10 BLOOD GROUPS: ABO AND Rh .........................................................77 CHAPTER 11 CELL-MEDIATED IMMUNITY AND MHC ........................................83 CHAPTER 12 CELL INTERACTIONS IN CELL MEDIATED IMMUNITY ..............91 CHAPTER 13 T-CELL/B-CELL COOPERATION IN HUMORAL IMMUNITY......105 CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES...............................................................111
    [Show full text]